Clinical Trial Update: SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial (SIMIDIS) evaluating azacitidine in combination with beta-erythropoietin for myelodysplastic syndrome has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Beta Erythropoietin (epoetin beta)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: TERMINATED